Building value by developing novel drugs for unmet needs using pragmatic approaches.


Cleveland BioLabs, Inc. (NASDAQ: CBLI)

Cleveland BioLabs, Inc. (Nasdaq:CBLI) is a clinical-stage biotechnology company with a focus on oncology and orphan drug development.

Since our inception in 2003, we have pursued the research, development and commercialization of proprietary products that have the potential to treat cancer, prevent and treat acute radiation syndrome and counteract the toxic effects of radio and chemotherapies for oncology patients.

Presently, we have nine product candidates in our pipeline that are being developed directly by us and our majority-owned subsidiaries, Incuron, LLC and Panacela Labs, Inc.

Investor Presentations

BIO-CEO and Investor February Presentation

Upcoming and Recent Events

Mar 11, 2014 at 10:00 AM ET
Cleveland BioLabs, Inc. Fourth Quarter and Fiscal 2013 Investor Update Call

View all »   RSSRecent Releases

Apr 16, 2014
Cleveland BioLabs Announces the Successful Completion of a Phase 1 Study of CBL0102

Apr 1, 2014
CBL0137 Combination Studies to Be Presented at 2014 AACR Annual Meeting

Annual Report

PDF 2012 Annual Report

Listed: Nasdaq
up   0.03
Delayed at least 20 minutes.
Provided by eSignal.

Investor Relations

Rachel Levine
Vice President, Investor Relations
Cleveland BioLabs, Inc.
Phone: +1 (646) 284-9439
Fax: +1 (716) 849-6820

Management Team

Yakov Kogan, Ph.D., MBA
Chief Executive Officer

Andrei Gudkov, Ph.D., D. Sci.
Chief Scientific Officer

C. Neil Lyons, CPA
Chief Financial Officer

Ann Hards, Ph.D.
Executive Vice President, Regulatory Affairs and Quality Assurance

Michelle Ross, DVM, MS, Ph.D.
Senior Vice President, Public Health and Government Affairs

Leah Brownlee, J.D.
Vice President, Compliance and Operations/Corporate Secretary

Anna Muchnik, MS
Vice President, Product Development

Andrei Purmal, Ph.D.
Vice President, Chemistry

Transfer Agent

Continental Stock Transfer & Trust Company.
17 Battery Place
8th Floor
New York, NY 10004
Tel: (212) 509-4000
Fax: (212) 509-5150


Meaden & Moore, Ltd.

You are now leaving this website. If you would like to continue, click Continue.